Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

BACKGROUND: The STREAM stage 1 trial showed that a 9-month regimen for the treatment of rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended regimen. In STREAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM stage 1 regimen....

詳細記述

保存先:
書誌詳細
出版年:Lancet
主要な著者: Goodall, Ruth L, Meredith, Sarah K, Nunn, Andrew J, Bayissa, Adamu, Bhatnagar, Anuj K, Bronson, Gay, Chiang, Chen-Yuan, Conradie, Francesca, Gurumurthy, Meera, Kirenga, Bruce, Kiria, Nana, Meressa, Daniel, Moodliar, Ronelle, Narendran, Gopalan, Ngubane, Nosipho, Rassool, Mohammed, Sanders, Karen, Solanki, Rajesh, Squire, S Bertel, Torrea, Gabriela, Tsogt, Bazarragchaa, Tudor, Elena, Van Deun, Armand, Rusen, ID
フォーマット: Artigo
言語:Inglês
出版事項: 2022
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614824/
https://ncbi.nlm.nih.gov/pubmed/36368336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(22)02078-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料